300966 Hubei Goto Biopharm
- 15.21
- -0.07-0.46%
Hubei Goto Biopharm News
Hubei Goto Biopharm: Announcement of the implementation of equity distribution in 2023.
Hubei Goto Biopharm: Announcement on shareholders and directors holding 5% or more of the company's shares reduced their holdings by 1% and the completion of the supervisors' holdings reduction plan
Hubei Goto Biopharm: Announcement on the abolition of restricted stocks that have been partially granted in the 2023 Restricted Stock Incentive Plan but have not yet been vested
Hubei Goto Biopharm: Announcement on the 2023 Profit Distribution Plan
Hubei Goto Biopharm: Legal Opinion of Beijing Zhonglun (Wuhan) Law Firm on the abolition of some restricted stocks in the 2023 Restricted Stock Incentive Plan of Hubei Kyodo Pharmaceutical Co., Ltd.
Kyodo Pharmaceutical: Pre-disclosure Notice on Reduction of Shareholdings by Shareholders, Directors and Supervisors Holding 5% or More of Their Shares
Kyodo Pharmaceutical: Explanation of the supervisory board's inspection opinions and disclosure on the list of incentive recipients reserved for the company's 2023 restricted stock incentive plan
Kyodo Pharmaceutical: Legal Opinion of Beijing Zhonglun (Wuhan) Law Firm on the 2023 Restricted Stock Incentive Plan Reservation and Grant of Hubei Kyodo Pharmaceutical Co., Ltd.
Kyodo Pharmaceutical: Supervisory Board's review opinion on the list of incentive recipients reserved for the company's 2023 restricted stock incentive plan (as of the grant date)
Kyodo Pharmaceutical: 2023 Restricted Stock Incentive Plan Reserve Award Recipient List (as of grant date)
Kyodo Pharmaceutical: Announcement on reserving and granting restricted shares to incentive recipients
Kyodo Pharmaceutical: Prompt announcement on the commencement of mutual debt conversion to shares
Kyodo Pharmaceutical: Announcement on the company's 2022 profit distribution plan
Kyodo Pharmaceutical: Announcement on the First Grant of Restricted Shares to Incentive Targets
Mutual Pharmaceutical: Legal opinion from Beijing Zhonglun (Wuhan) Law Firm on the first award of Hubei Gongyang Pharmaceutical Co., Ltd.'s 2023 restricted stock incentive plan
Kyodo Pharmaceutical: List of incentive recipients granted for the first time in the 2023 Restricted Stock Incentive Plan (as of the grant date)
Mutual Pharmaceutical: Supervisory Board's Review Opinions on the Company's 2023 Restricted Stock Incentive Plan for the First Time Grant of the Incentives List (as of the Grant Date)
Kyodo Pharmaceutical: Self-inspection report on insider information insiders of the 2023 Restricted Stock Incentive Plan and the incentive targets trading the company's shares
Mutual Pharmaceutical: Supervisory Board's Verification Opinions and Publication Information Note on the List of Incentive Targets for the First Time in the Company's 2023 Restricted Stock Incentive Plan
Mutual Pharmaceutical: Supervisory Board's Review Opinions on Matters Relating to the Company's 2023 Restricted Stock Incentive Plan
Analysis
Price Target
No Data
